信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

已收盘 06-08 16:09:02

73.250

-3.350

-4.37%

最高75.150	最低71.950	成交量1,461万
今开74.800	昨收76.600	日振幅4.18%
总市值1,273亿	流通市值1,273亿	总股本17.38亿
成交额10.76亿	换手率0.84%	流通股本17.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":73.25,"timestamp":1780906142004,"preClose":76.6,"halted":0,"volume":14606270,"delay":0,"changeRate":-0.04373368146214092,"floatShares":1738000000,"shares":1738000000,"eps":0.5430867133566313,"marketStatus":"已收盘","change":-3.35,"latestTime":"06-08 16:09:02","open":74.8,"high":75.15,"low":71.95,"amount":1075630910,"amplitude":0.041775,"askPrice":73.25,"askSize":16500,"bidPrice":73.2,"bidSize":28000,"shortable":3,"etf":0,"ttmEps":0.5430867133566313,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780968600000},"marketStatusCode":5,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":76.6,"openAndCloseTimeList":[[1780882200000,1780891200000],[1780894800000,1780905600000]],"volumeRatio":1.005205,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.3588,"impliedVolPercentile":0.0732},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2641827334","title":"两大减肥药巨头国际大会“火拼”数据，信达生物三项研究获口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2641827334","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641827334?lang=zh_cn&edition=full","pubTime":"2026-06-08 21:24","pubTimestamp":1780925040,"startTime":"0","endTime":"0","summary":"借势学术盛会的聚光灯，减重药的热度再次在全球医药行业中被点燃。6月5日至8日，第86届美国糖尿病协会（ADA）科学年会召开。该年会是全球糖尿病、肥胖症及代谢疾病领域最具影响力的国际学术会议之一，每年都吸引着众多创新药企来参加。肥胖与糖尿病密切相关，本届ADA年会毫无悬念地成了GLP-1减肥药的研究结果的“秀场”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606083763872482.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606083763872482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU2097828714.EUR","LU2328871848.SGD","BK1589","LU2097828631.EUR","LU2097828474.EUR","HK0000165453.HKD","LU0455707207.USD","LU1969619763.USD","01801","LU2242644610.SGD","LU2097828805.USD","LU2488822045.USD","LU0502904849.HKD","LU2097828557.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162781171","title":"信达生物展示下一代肥胖与代谢疾病管线多项临床及临床前成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1162781171","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162781171?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:33","pubTimestamp":1780907587,"startTime":"0","endTime":"0","summary":"2026年艾达 | 信达生物（INNOVENT BIO）公布了其下一代针对肥胖与代谢疾病的产品管线所取得的多项临床及临床前研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","LU2242644610.SGD","LU0455707207.USD","LU2097828557.USD","HK0000165453.HKD","BK1583","LU0502904849.HKD","LU1969619763.USD","LU2097828714.EUR","LU2328871848.SGD","LU2488822045.USD","01801","LU2097828474.EUR","BK1589","LU2097828631.EUR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641101540","title":"港股异动 | 创新药概念股全线承压 流动性收紧直接压制板块估值 机构指BINSA草案影响偏情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=2641101540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641101540?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:08","pubTimestamp":1780902518,"startTime":"0","endTime":"0","summary":"消息面上，中东紧张局势推高能源价格之际，劳动力市场表现强劲，强化了市场对美联储年内加息的押注。国海证券此前在风险提示中指出，若全球及国内宏观货币政策节奏不及预期，将直接影响医药板块的估值水平与投融资环境。创新药、CXO等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。此外，6月2日，美国《生物技术投资国家安全法》法案公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287792.SGD","BK1574","IE00B5MMRT66.SGD","LU0501845795.SGD","LU1960683339.HKD","VXUS","159992","LU2039709279.SGD","LU1008478684.HKD","LU2488822045.USD","01801","LU0072913022.USD","LU2097828714.EUR","BK4588","BK4585","LU1152091168.USD","01093","IE0008369823.USD","01177","LU1993786604.SGD","IE00B543WZ88.USD","LU1969619763.USD","SG9999004220.SGD","LU1328277881.USD","HK0000165453.HKD","06978","BK1593","01530","LU0140636845.USD","LU2097828631.EUR","LU0314109678.HKD","LU0455707207.USD","BK1515","BK1583","LU0502904849.HKD","LU2242644610.SGD","BK1191","LU1226288253.USD","LU2097828557.USD","LU1813983027.USD","BK1161","IE00BZ08YT58.USD","LU0880133367.SGD","IE00B031HY20.USD","LU1226287875.USD","LU1951186391.HKD","BK1589","LU1226288170.HKD","LU2328871848.SGD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641177986","title":"东方证券：国产创新药开启NSCLC一线治疗范式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2641177986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641177986?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:55","pubTimestamp":1780883706,"startTime":"0","endTime":"0","summary":"东方证券主要观点如下：一代PD-1单药±化疗标准松动，NSCLC一线进入二代IO、ADC+IO双线迭代周期本届ASCO大会上，来自国产创新药的三项重磅临床数据表明，NSCLC一线金标准，即传统的PD-1±化疗的正迎来系统性替代。在免疫1.0时代，国产创新药大多跟随海外PD-1药物的研发，如今快速发展至引领免疫2.0时代，有望创造肺癌千亿市场治疗范式的全面革新。该研究是全球首个ADC+IO一线NSCLC取得III期阳性结果，有望改写PD-L1阳性NSCLC一线用药格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","IE00B5MMRT66.SGD","LU0348767384.USD","159992","LU2476274720.SGD","LU2488822045.USD","LU2778985437.USD","01801","LU0540923850.HKD","LU0348827113.USD","LU2097828714.EUR","BK0012","LU2476274308.USD","LU0561508036.HKD","LU0348766576.USD","LU0348735423.USD","LU0417516738.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU0417516571.SGD","LU1794554557.SGD","LU1969619763.USD","03958","HK0000165453.HKD","06978","LU2097828631.EUR","06990","LU0348825331.USD","LU2097828474.EUR","IE00BPRC5H50.USD","LU0417516902.SGD","BK0276","LU0455707207.USD","BK1147","BK1564","LU0348783233.USD","BK0183","LU0502904849.HKD","LU2097828805.USD","600958","LU2097828557.USD","BK0028","LU0348784397.USD","BK1161","LU0196878994.USD","LU0634319403.HKD","LU1961090484.USD","BK1589","09926","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158803850","title":"异动解读｜信达生物盘中下跌3.59%，辉瑞合作监管审批不确定性持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1158803850","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158803850?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:50","pubTimestamp":1780883424,"startTime":"0","endTime":"0","summary":"6月8日，信达生物盘中下跌3.59%，报74.8港元/股，成交额2.4亿港元。公司此前宣布与辉瑞签署105亿美元全球战略合作协议，股价5月29日大涨逾11%后已连续多个交易日回调。消息面上，市场对该交易能否顺利获得监管批准持续存疑。此外，生物科技板块内三生制药跌2.74%、康方生物跌1.44%，板块部分个股弱势对信达生物形成共振拖累。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101562555","title":"异动解读｜信达生物盘中上涨3.01%，胃癌新药全球首家获受理叠加板块回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=1101562555","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101562555?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:55","pubTimestamp":1780624505,"startTime":"0","endTime":"0","summary":"6月5日，信达生物盘中上涨3.01%，报79.5港元/股，成交额3.27亿港元。消息面上，公司6月4日宣布其CLDN18.2 ADC药物IBI343用于晚期胃癌的新药上市申请获中国国家药监局受理并获优先审评，成为全球首个进入监管审查的CLDN18.2靶向ADC药物。该药物在国际多中心III期临床研究中达到PFS、OS双主要终点，若获批有望填补晚期胃癌后线治疗的临床空白。此外，生物科技板块今日整体回暖，科伦博泰生物涨5.95%、康方生物涨3.17%、荣昌生物涨2.21%，板块共振提振信达生物股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115562939","title":"全球首款CLDN18.2 ADC进入监管审查：信达生物宣布Ibi343（Arcotatug Tavatecan）在晚期难治性胃癌国际三期研究中达到主要终点，新药上市申请获中国NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1115562939","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115562939?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:36","pubTimestamp":1780562178,"startTime":"0","endTime":"0","summary":"信达生物宣布，其靶向CLDN18.2的抗体偶联药物Ibi343（Arcotatug Tavatecan）在一项针对晚期难治性胃癌的国际三期临床研究中，成功达到了预设的主要研究终点。与此同时，该药物的新药上市申请已获得中国国家药品监督管理局的正式受理。\n这意味着，Ibi343有望成为全球范围内首款进入监管审查阶段的CLDN18.2靶向抗体偶联药物。该研究结果展现了其在治疗这一极具挑战性的癌症适应症方面的潜力。新药上市申请的受理，标志着该药物向商业化迈出了关键一步，为晚期胃癌患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","HK0000165453.HKD","LU2097828631.EUR","01801","LU0502904849.HKD","LU1969619763.USD","LU2488822045.USD","BK1589","LU2242644610.SGD","LU2328871848.SGD","LU2097828557.USD","BK1583","LU2097828805.USD","LU2097828714.EUR","BK1161","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640153816","title":"信达生物(01801): IBI343(CLDN18.2 ADC)治疗晚期胃癌的新药上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640153816","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640153816?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:34","pubTimestamp":1780562045,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，IBI343用于晚期胃癌人群的国际III期临床研究按预设方案完成第一次期中分析，达到主要研究终点，IBI343在晚期胃癌治疗中展现出了卓越的疗效和良好的安全性和耐受性。基于这一积极的临床结果，公司已向中国国家药品监督管理局递交IBI343的新药上市申请。IBI343是全球首个获监管审评受理的CLDN18.2靶向ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0455707207.USD","LU0502904849.HKD","LU1969619763.USD","LU2097828714.EUR","ADC","IPOS","BK4080","LU2097828474.EUR","BK1589","LU2097828805.USD","HK0000165453.HKD","LU2488822045.USD","LU2242644610.SGD","BK1161","01801","BK4231","BK1583","LU2097828631.EUR","LU2328871848.SGD","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640378531","title":"西南证券：信达生物(01801)携手辉瑞 加速创新肿瘤药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2640378531","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640378531?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:15","pubTimestamp":1780553754,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，西南证券发布研报称，5月29日，信达生物与辉瑞达成全球战略合作，加速创新肿瘤药物开发。同时，信达保留在大中华区地区的权利；根据协议的财务条款，信达生物将获得首付款6.5亿美元，并有资格获得最高可达98.5亿美元的研发、监管与商业化里程碑付款，交易总额达105亿美元。在2026ASCO上，信达生物公布了IBI363一线治疗晚期NSCLC的临床I期PoC研究初步结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BBT3K403.USD","LU0502904849.HKD","SG9999011175.SGD","LU0321505868.SGD","IE00BLSP4239.USD","LU1883839398.USD","LU2097828805.USD","LU1057294990.SGD","PFE","LU1894683264.USD","LU1023059063.AUD","LU2097828557.USD","BK4592","BK4534","BK4581","BK4550","01801","IE0002270589.USD","BK4007","LU2488822045.USD","IE00B3T34201.USD","BK4588","LU2097828474.EUR","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0234572021.USD","SG9999013999.USD","LU1066053197.SGD","LU0455707207.USD","LU0122379950.USD","LU0225284248.USD","LU0321505439.SGD","BK1583","SG9999002232.USD","SGXZ57979304.SGD","SG9999003800.SGD","SG9999001176.USD","LU1969619763.USD","LU2328871848.SGD","IE00BLSP4452.SGD","LU0306806265.USD","BK4533","LU0170899867.USD","SG9999001176.SGD","HK0000165453.HKD","BK4585","BK4599","LU0058720904.USD","LU1894683348.USD","BK1161","BK1589","BK4568","LU0225771236.USD","SG9999002224.SGD","LU0306807586.USD","LU0868494617.USD","IE000M9KFDE8.USD","LU1066051498.USD","LU0985481810.HKD","LU2097828631.EUR","LU2097828714.EUR","LU0289739699.SGD","LU2242644610.SGD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2640979525","title":"交银国际：维持信达生物(01801)“买入”评级 目标价105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640979525","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640979525?lang=zh_cn&edition=full","pubTime":"2026-06-03 14:11","pubTimestamp":1780467074,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，信达生物维持“买入”评级和105港元的目标价，看好临床数据读出和BD交易持续催化股价复苏。交银国际主要观点如下：IBI363两项肺癌重磅研究闪耀ASCO大会IBI363治疗1LNSCLC和I/O耐药NSCLC的PoC数据在ASCO大会上公布：1）1LNSCLC：在优化后的给药剂量下，确认ORR、未确认ORR和DCR分别达到82%、86%和100%，优于1.5mg/kg和3mg/kg剂量组。安全性整体良好，3→1.5mg/kg剂量组中，≥3级IBI363相关AE发生率43.5%，低于1.5mg/kg和3mg/kg剂量组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104334770","title":"异动解读｜信达生物盘中下跌3.04%，辉瑞合作监管审批不确定性叠加生物科技板块持续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1104334770","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104334770?lang=zh_cn&edition=full","pubTime":"2026-06-03 10:00","pubTimestamp":1780452025,"startTime":"0","endTime":"0","summary":"6月3日，信达生物盘中下跌3.04%，报76.45港元/股，成交额2.34亿港元。公司此前宣布与辉瑞签署105亿美元全球战略合作协议，股价5月29日大涨逾11%后已连续多日回调。消息面上，市场对该交易能否顺利获得监管批准持续存疑。此外，生物科技板块今日整体延续弱势，康方生物跌3.76%、荣昌生物跌3.91%、三生制药跌3.44%、云顶新耀跌2.69%、百济神州跌2.49%，板块系统性抛压对信达生物形成共振拖累。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640276429","title":"【券商聚焦】交银国际维持信达生物(01801)买入评级 指重磅合作验证早研管线差异化优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2640276429","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640276429?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:18","pubTimestamp":1780449499,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，信达生物 IBI363治疗1L NSCLC和I/O耐药NSCLC的PoC数据在ASCO大会上公布：1）1L NSCLC：在优化后的给药剂量下，确认ORR、未确认ORR和DCR分别达到82%、86%和100%，优于1.5mg/kg和3mg/kg剂量组。本次交易是公司继礼来、罗氏和武田后再次与MNC达成深度合作，Co-Co项目数量之多创下国产创新药出海的记录，也侧面印证了公司产品强大的差异化竞争优势。维持买入评级和105港元的目标价，看好临床数据读出和BD交易持续催化股价复苏。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982885","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133333356","title":"异动解读 | 信达生物盘中大跌5.01%，辉瑞合作监管审批不确定性及板块抛压拖累股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1133333356","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133333356?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:48","pubTimestamp":1780364931,"startTime":"0","endTime":"0","summary":"信达生物今日盘中股价大跌5.01%，引发市场关注。消息面上，公司此前宣布与辉瑞签署一项105亿美元的全球战略合作协议，但市场关注点集中于该交易仍需取得监管批准。近期关于生物医药领域出口管制目录可能修订的传闻，以及美国COINS法案对生物技术行业的潜在限制，共同加剧了市场对交易获批不确定性的担忧，持续压制了投资者情绪。此外，生物科技板块今日整体表现疲软，板块内多只个股出现显著下跌，形成了系统性的抛售压力，这也对信达生物的股价产生了共振拖累效应。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178764270","title":"异动解读｜信达生物盘中下跌3.15%，辉瑞合作监管审批不确定性叠加生物科技板块持续回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1178764270","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178764270?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:43","pubTimestamp":1780364598,"startTime":"0","endTime":"0","summary":"6月2日，信达生物盘中下跌3.15%，报77.35港元/股，成交额1.45亿港元。消息面上，公司5月29日宣布与辉瑞签署105亿美元全球战略合作协议，股价当日大涨逾11%后连续回调。此外，生物科技板块今日整体大幅走弱，康方生物跌8.02%、科伦博泰生物跌7.90%、三生制药跌7.72%、荣昌生物跌4.78%、百济神州跌3.67%，板块系统性抛压对信达生物形成共振拖累。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640330789","title":"【券商聚焦】中信建投维持信达生物(01801)“买入”评级 指其与辉瑞合作全球化里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2640330789","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640330789?lang=zh_cn&edition=full","pubTime":"2026-06-01 13:55","pubTimestamp":1780293323,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，信达生物 与辉瑞达成全球战略合作，交易总额达105亿美元。信达生物将获得首付款6.5亿美元，并有资格获得最高达98.5亿美元的研发、监管与商业化里程碑付款，对于每一款获批项目还将获得最高达双位数比例的销售分成。中信建投预计信达生物2026-2028年收入分别为180.2亿元、243.3亿元、285.8亿元，净利润分别为22.1亿元、38.2亿元、50.1亿元。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982638","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU1894683264.USD","LU0306806265.USD","LU1023059063.AUD","BK4007","SG9999001176.SGD","LU0456855351.SGD","BK4592","SG9999001176.USD","01801","BK4599","IE00BLSP4452.SGD","LU2242644610.SGD","SGXZ57979304.SGD","SG9999011175.SGD","BK1583","IE00B19Z3B42.SGD","BK4588","LU0170899867.USD","LU1066053197.SGD","LU0321505439.SGD","IE00BBT3K403.USD","LU0321505868.SGD","LU0306807586.USD","LU0502904849.HKD","LU2097828805.USD","BK4533","LU0234572021.USD","LU2097828474.EUR","BK4585","BK4550","LU1969619763.USD","LU0225771236.USD","BK1589","IE00B19Z3581.USD","LU0289739699.SGD","LU0985481810.HKD","LU2097828714.EUR","LU0058720904.USD","LU1066051498.USD","LU2328871848.SGD","IE000M9KFDE8.USD","LU0225284248.USD","LU1057294990.SGD","LU1883839398.USD","LU1894683348.USD","BK4568","LU0122379950.USD","LU2097828557.USD","LU2097828631.EUR","IE00BLSP4239.USD","PFE","LU0868494617.USD","BK4534","BK4581","IE0002270589.USD","IE00B3T34201.USD","LU0455707207.USD","LU2488822045.USD","HK0000165453.HKD","BK1161","SG9999002224.SGD","SG9999003800.SGD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194842596","title":"异动解读｜信达生物盘中下跌3.12%，辉瑞合作监管审批不确定性叠加板块回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1194842596","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194842596?lang=zh_cn&edition=full","pubTime":"2026-06-01 11:17","pubTimestamp":1780283842,"startTime":"0","endTime":"0","summary":"6月1日，信达生物盘中下跌3.12%，报80.75港元/股，成交额6.33亿港元。此外，生物科技板块今日整体偏弱，百济神州跌3.45%、荣昌生物跌5.32%、科伦博泰生物跌4.11%，板块系统性回调对信达生物形成共振拖累。信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢、自身免疫及眼科等重大疾病创新药物的投资控股公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154512740","title":"2026 ASCO | 信达生物发布IBI363长期随访数据，在免疫疗法耐药晚期非小细胞肺癌中展现强劲生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1154512740","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154512740?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:00","pubTimestamp":1780272044,"startTime":"0","endTime":"0","summary":"在2026年美国临床肿瘤学会（ASCO）年会上，信达生物公布了其概念验证研究中IBI363（TAK-928）的长期随访结果。IBI363是一种靶向PD-1与IL-2α偏向性的双特异性融合蛋白。数据显示，该药物为对现有免疫疗法产生耐药性的晚期非小细胞肺癌患者带来了显著的生存益处。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1589","LU0455707207.USD","LU0502904849.HKD","01801","BK1583","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","LU2097828805.USD","LU2097828474.EUR","LU2097828631.EUR","LU2097828714.EUR","LU2097828557.USD","HK0000165453.HKD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639450605","title":"信达牵手辉瑞，给中国Biopharma全球化打了个样","url":"https://stock-news.laohu8.com/highlight/detail?id=2639450605","media":"医曜","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639450605?lang=zh_cn&edition=full","pubTime":"2026-05-30 09:01","pubTimestamp":1780102881,"startTime":"0","endTime":"0","summary":"信达授予辉瑞全球独家许可权，辉瑞承担全球开发成本。这并不是第一次有中国Biopharma尝试进入全球商业化，但却是第一次以如此系统的方式、在如此大规模的框架下实现。中国Biopharma的长期估值天花板，取决于它能不能从“管线供给方”变成“全球品牌药企”。在这条路径上，Biopharma不需要卖断管线，不需要放弃全球品牌建设的可能性，可以用研发能力换取商业化能力的合伙权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8tXhUm8ykvO","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["LU0058720904.USD","LU0234572021.USD","BK4534","LU1066053197.SGD","BK4533","SG9999013999.USD","LU0225284248.USD","LU0306807586.USD","LU2097828631.EUR","IE00B19Z3B42.SGD","LU2328871848.SGD","IE00BLSP4239.USD","SG9999011175.SGD","BK4568","LU0868494617.USD","SG9999003800.SGD","LU2097828805.USD","LU1883839398.USD","SG9999001176.SGD","LU2242644610.SGD","SG9999002232.USD","LU0455707207.USD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1066051498.USD","LU1023059063.AUD","LU0321505439.SGD","LU2097828557.USD","BK4585","LU2097828714.EUR","BK4007","LU0456855351.SGD","01801","LU1894683348.USD","BK1589","LU0122379950.USD","PFE","IE00B3T34201.USD","SG9999001176.USD","BK4550","IE00B19Z3581.USD","BK1161","LU0321505868.SGD","LU2097828474.EUR","BK4588","IE00BLSP4452.SGD","HK0000165453.HKD","LU0289739699.SGD","LU0225771236.USD","LU0502904849.HKD","LU1969619763.USD","SG9999002224.SGD","IE0002270589.USD","LU2488822045.USD","LU0170899867.USD","BK4599","BK4592","IE00BBT3K403.USD","BK4581","BK1583","LU0306806265.USD","SGXZ57979304.SGD","LU1894683264.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639673697","title":"信达生物官宣百亿美元BD订单，盘中股价涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639673697","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639673697?lang=zh_cn&edition=full","pubTime":"2026-05-29 21:54","pubTimestamp":1780062840,"startTime":"0","endTime":"0","summary":"5月29日，信达生物（1801.HK）盘中最高涨超13%，收涨11.36%，报83.35港元/股，市值1448.8亿港元。消息面上，信达生物与辉瑞公司就12个具有突破性潜力的肿瘤早期及源头创新研发项目签署全球战略合作协议。本次合作涵盖由12个项目构成的肿瘤产品组合，包括8个信达生物的早期管线，及4个将由辉瑞提议的全新（denovo）项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605293754726025.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754726025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1589","LU0455707207.USD","LU0502904849.HKD","01801","BK1583","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","LU2097828805.USD","LU2097828474.EUR","LU2097828631.EUR","LU2097828714.EUR","LU2097828557.USD","HK0000165453.HKD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143583435","title":"信达生物授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1143583435","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143583435?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:46","pubTimestamp":1780044407,"startTime":"0","endTime":"0","summary":"信达生物发布公告称，公司董事会审议通过了一项股份购回授权，计划在股东周年大会授予董事购回公司不超过其已发行股本10%的股份的权限。以2026年5月26日最后可行日期统计，信达生物已发行股本为17.38亿股，在授权范围内可回购的最高股份数量约为1.74亿股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.081},{"period":"1month","weight":-0.1545},{"period":"3month","weight":-0.0804},{"period":"6month","weight":-0.1674},{"period":"1year","weight":0.0595},{"period":"ytd","weight":0.0046}],"compareEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0478},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0431},{"period":"1year","weight":0.0441},{"period":"ytd","weight":-0.0261}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.014737},{"month":6,"riseRate":0.625,"avgChangeRate":0.111646},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}